O-18 DIFFERENCES IN BODY COMPOSITION OF MAFLD PATIENTS ACCORDING TO BODY MASS INDEX AND METABOLIC PROFILE

Introduction and Objectives

Body composition (BC) has been linked to liver steatosis. The aim of this study is to describe differences in BC in MAFLD patients.

Materials and Methods

Liver steatosis was evaluated by controlled attenuation parameter, patients were classified according to body mass index (BMI) and definitions of MAFLD in five groups: G1:<25kg/m2-non-MAFLD; G2: <25kg/m2-MAFLD; G3: 25-30kg/m2-MAFLD; G4:>30kg/m2-MAFLD and metabolically healthy (<3 metabolic abnormalities) (MH) and G5: >30kg/m2-MAFLD and metabolically unhealthy (MU). BC was assessed by bioelectrical impedance obtaining measurements of resistance; reactance; phase angle; percentages of fat; total body water (TBW%); intracellular and extracellular water (ICW%, ECW%) and skeletal muscle mass (SMM%). Differences in BC was analyzed by Kruskall-Wallis test. Continuous data showed as median and IQR.

Results

140 patients were included (G1 n=30; G2 n=24; G3 n=30; G4 n=26; G5 n=30). 56.4% (n=79) were male with median of age of 49 [41- 55] years. Overweight/obese MAFLD patients showed significant lower resistance and reactance levels (p0.05). According to vectorial analysis, chaquexia was observed in 18.4% (n=7) of patients in G4 and 15.8% (n=6) in G5 patients. Fat% was higher in patients of G5 (MU) than G2 (34.3[29.8-40.4], p=0.02) and G3 (35[31.1-38.3], p=0.01). Obese MAFLD patients showed lower TBW%, ICW% and ECW% (p0.001). (Figure). SMM% was lower in MU obese patients (29.1[26.3-31.1]) compared to healthy controls (33.4[29.3-36.8], p=0.006) and overweight patients (32[29.7-34.4], p=0.02). Phase angle did not show significant differences.

Conclusions

Overweight/obese MAFLD patients shows BC abnormalities in comparison with healthy controls and lean MAFLD patients. Resistance, reactance, body water and skeletal muscle mass are significant lower in both metabolically healthy/unhealthy obese patients. Changes could be explained for the sarcopenia and fat-muscle interchange and no necessary for the presence of metabolic abnormalities.